Table 2 Results of susceptibility testing of 16 antimicrobial agents against RGM
From: Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan
RGM species (No. of isolates tested) and antimicrobial agent | MIC (μg/mL) | Percentage of isolates | ||||
|---|---|---|---|---|---|---|
Range | MIC50 | MIC90 | S | I | R | |
M. abscessus complex (13) | ||||||
Amikacin | 8–16 | 16 | 16 | 100 | 0 | 0 |
Tobramycin | 8– >16 | 16 | >16 | 0 | 0 | 100 |
Tigecycline | ≤0.12–0.5 | 0.25 | 0.5 | 100 | -a | 0 |
Minocycline | ≤0.25– >16 | >16 | >16 | 15.4 | 15.4 | 69.2 |
Ciprofloxacin | 4– >8 | >8 | >8 | 0 | 0 | 100 |
Moxifloxacin | 2– >8 | 8 | >8 | 0 | 7.7 | 92.3 |
Clarithromycin | ≤0.25– >32 | 0.5 | >32 | 61.5 | 7.7 | 30.8 |
Azithromycin | ≤1– >16 | 16 | >16 | - | - | - |
Linezolid | ≤2–32 | 4 | 16 | 76.9 | 15.4 | 7.7 |
Imipenem | 2–16 | 8 | 16 | 30.8 | 69.2 | 0 |
Meropenem | 8–64 | 16 | 32 | 0 | 69.2 | 30.8 |
Faropenem | >2 | >2 | >2 | - | - | - |
Tebipenem | 4– >4 | >4 | >4 | - | - | - |
Cefmetazole | 8–64 | 32 | 32 | - | - | - |
Cefepime | 32– >64 | 64 | >64 | - | - | - |
Sulfamethoxazole | >152 | >152 | >152 | 0 | - | 100 |
M. chelonae (12) | ||||||
Amikacin | ≤4–64 | 16 | 16 | 91.7 | 0 | 8.3 |
Tobramycin | ≤1–4 | 2 | 4 | 83.3 | 16.7 | 0 |
Tigecycline | ≤0.12–0.25 | ≤0.12 | 0.25 | 100 | - | 0 |
Minocycline | 8– > 16 | 16 | >16 | 0 | 0 | 100 |
Ciprofloxacin | ≤0.25– >8 | 8 | >8 | 16.7 | 8.3 | 75.0 |
Moxifloxacin | ≤0.25–8 | 2 | 4 | 16.7 | 41.7 | 41.7 |
Clarithromycin | ≤0.25 | ≤0.25 | ≤0.25 | 100 | 0 | 0 |
Azithromycin | ≤1–2 | ≤1 | 2 | - | - | - |
Linezolid | ≤2–8 | ≤2 | 8 | 100 | 0 | 0 |
Imipenem | ≤1–16 | 4 | 8 | 58.3 | 41.7 | 0 |
Meropenem | ≤1–64 | 64 | 64 | 8.3 | 8.3 | 83.3 |
Faropenem | ≤0.25– >2 | >2 | >2 | - | - | - |
Tebipenem | ≤0.5– >4 | >4 | >4 | - | - | - |
Cefmetazole | ≤4– >128 | >128 | >128 | - | - | - |
Cefepime | ≤2–64 | 16 | 32 | - | - | - |
Sulfamethoxazole | 38– >152 | >152 | >152 | 8.3 | - | 91.7 |
M. fortuitum (9) | ||||||
Amikacin | ≤4 | ≤4 | ≤4 | 100 | 0 | 0 |
Tobramycin | 16– >16 | >16 | >16 | 0 | 0 | 100 |
Tigecycline | ≤0.12 | ≤0.12 | ≤0.12 | 100 | - | 0 |
Minocycline | ≤0.25– >16 | ≤0.25 | >16 | 55.6 | 0 | 44.4 |
Ciprofloxacin | ≤0.25 | ≤0.25 | ≤0.25 | 100 | 0 | 0 |
Moxifloxacin | ≤0.25 | ≤0.25 | ≤0.25 | 100 | 0 | 0 |
Clarithromycin | 4– >32 | 32 | >32 | 0 | 11.1 | 88.9 |
Azithromycin | >16 | >16 | >16 | - | - | - |
Linezolid | 4–16 | 8 | 16 | 88.9 | 11.1 | 0 |
Imipenem | ≤1–8 | 2 | 8 | 66.7 | 33.3 | 0 |
Meropenem | 4–8 | 4 | 8 | 66.7 | 33.3 | 0 |
Faropenem | >2 | >2 | >2 | - | - | - |
Tebipenem | 1–4 | 2 | 4 | - | - | - |
Cefmetazole | 8–16 | 16 | 16 | - | - | - |
Cefepime | >64 | >64 | >64 | - | - | - |
Sulfamethoxazole | 76– >152 | >152 | >152 | 0 | - | 100 |
M. mageritense (4) | ||||||
Amikacin | ≤4– >128 | 128 | >128 | 25.0 | 0 | 75.0 |
Tobramycin | >16 | >16 | >16 | 0 | 0 | 100 |
Tigecycline | ≤0.12 | ≤0.12 | ≤0.12 | 100 | - | 0 |
Minocycline | 2– >16 | 2 | >16 | 0 | 50.0 | 50.0 |
Ciprofloxacin | ≤0.25–1 | ≤0.25 | 1 | 100 | 0 | 0 |
Moxifloxacin | ≤0.25 | ≤0.25 | ≤0.25 | 100 | 0 | 0 |
Clarithromycin | 32– >32 | >32 | >32 | 0 | 0 | 100 |
Azithromycin | 16– >16 | 16 | >16 | - | - | - |
Linezolid | ≤2–16 | ≤2 | 16 | 75.0 | 25.0 | 0 |
Imipenem | ≤1–2 | ≤1 | 2 | 100 | 0 | 0 |
Meropenem | ≤1–4 | ≤1 | 4 | 100 | 0 | 0 |
Faropenem | 2– >2 | 2 | >2 | - | - | - |
Tebipenem | 1–4 | 2 | 4 | - | - | - |
Cefmetazole | ≤4–8 | ≤4 | 8 | - | - | - |
Cefepime | >64 | >64 | >64 | - | - | - |
Sulfamethoxazole | ≤19– >152 | 152 | >152 | 25.0 | - | 75.0 |
M. peregrinum (2) | ||||||
Amikacin | ≤4 | ≤4 | ≤4 | 100 | 0 | 0 |
Tobramycin | 4–8 | 4 | 8 | 0 | 50.0 | 50.0 |
Tigecycline | ≤0.12 | ≤0.12 | ≤0.12 | 100 | - | 0 |
Minocycline | >16 | >16 | >16 | 0 | 0 | 100 |
Ciprofloxacin | ≤0.25 | ≤0.25 | ≤0.25 | 100 | 0 | 0 |
Moxifloxacin | ≤0.25 | ≤0.25 | ≤0.25 | 100 | 0 | 0 |
Clarithromycin | ≤0.25 | ≤0.25 | ≤0.25 | 100 | 0 | 0 |
Azithromycin | ≤1– >16 | ≤1 | >16 | - | - | - |
Linezolid | 4–8 | 4 | 8 | 100 | 0 | 0 |
Imipenem | ≤1–2 | ≤1 | 2 | 100 | 0 | 0 |
Meropenem | 2–4 | 2 | 4 | 100 | 0 | 0 |
Faropenem | >2 | >2 | >2 | - | - | - |
Tebipenem | ≤0.5–1 | ≤0.5 | 1 | - | - | - |
Cefmetazole | ≤4–8 | ≤4 | 8 | - | - | - |
Cefepime | >64 | >64 | >64 | - | - | - |
Sulfamethoxazole | 38– >152 | 38 | >152 | 50.0 | - | 50.0 |